INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY;경상대학교산학협력단
发明人:
KIM, Myeong Ok,김명옥
申请号：
KRKR2017/004150
公开号：
WO2018/182085A1
申请日:
2017.04.18
申请国别(地区):
KR
年份:
2018
代理人:
摘要：
An osmotin protein of the present invention is non-cytotoxic, inhibits cell surface expression of CD14 and a TLR4 protein, which are LPS receptors, inhibits the activation of NF-κB through the inhibition of the phosphorylation of IκBα, and suppresses the expression of cyclooxygenase-2 (COX-2) inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), and Interleukin-1β (IL-1β), thereby being usable in anti-inflammatory or immunopotentiating health functional foods or drugs.L'invention concerne une protéine osmotine qui est non cytotoxique, inhibe l'expression en surface cellulaire de CD14 et d'une protéine TLR4, qui sont des récepteurs LPS, inhibe l'activation de NF-κB par l'inhibition de la phosphorylation d'IκBα, et supprime l'expression de l'oxyde nitrique synthase inductible par la cyclo-oxygénase-2 (COX-2) (iNOS), le facteur de nécrose tumorale α (TNF-α), et l'interleukine 1ß (IL-1ß), et qui peut donc être utilisée dans des aliments de santé ou des médicaments anti-inflammatoires ou immunopotentialisateurs.본 발명의 오스모틴 단백질은 세포독성이 없으며, LPS 수용체인 CD14 및 TLR4 단백질의 세포 표면 발현을 억제하고, IκBα 인산화 억제를 통해 NF-κB의 활성화를 억제시킬 뿐만 아니라, COX-2(cyclooxygenase-2), iNOS(inducible nitric oxide synthase), TNF-α(tumor necrosis factor-α) 및 IL-1β(Interleukin-1β)의 발현을 저해하므로, 항염증 또는 면역증강을 위한 건강기능식품 또는 의약품에 유용하게 사용될 수 있다.
